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 Introduction 
 Cortisol, the most potent physiologic glucocorticoid, 
affects almost all physiologic systems of the organism. 
Cortisol is synthesised and released from the adrenal cor-
tex under hypothalamic control in a pulsatile and circa-
dian way. Importantly, under stress the adrenals secrete 
cortisol on top of this rhythm, which facilitates recovery. 
In case of immune challenge, cortisol protects the organ-
ism against damaging infl ammatory responses. Due to 
the multiple targets of action, cortisol and more impor-
tantly synthetic derivatives are fi rst-line drugs in the 
treatment of immunologic and infl ammatory diseases, as 
for example infl ammatory bowel disease, arthritis and 
systemic lupus erythematosus. Moreover, glucocorticoids 
are effective in the treatment of some neoplastic diseases, 
e.g. acute lymphatic leukemia of children. 
 In many infl ammatory skin diseases  [1] as well as in 
persistent bronchial asthma  [2] , topical glucocorticoids 
are a mainstay of therapy, as unwanted effects are less 
prominent compared with systemic treatment. With re-
spect to the skin, antiproliferative, apoptotic or antiapop-
totic and also vasoconstrictive effects may contribute to 
the desired anti-infl ammatory and immunosuppressive 
effects, yet may also result in unwanted side effects in 
other diseases. Moreover, it has been learnt that glucocor-
ticoids do not only differ with respect to potency but also 
in the benefi t/risk ratio  [3] , which is linked to a selective 
infl uence on cytokine synthesis  [4, 5] . While this was fi rst 
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 Abstract 
 Topical glucocorticoids have always been considered 
fi rst-line drugs for infl ammatory diseases of the skin and 
bronchial system. Applied systemically, glucocorticoids 
are used for severe infl ammatory and immunological 
diseases and the inhibition of transplant rejection. Ow-
ing to the progress in molecular pharmacology, the 
knowledge of the mechanism of action has increased 
during the last years. Besides distinct genomic targets, 
which are due to the activation of specifi c cytoplasmatic 
receptors resulting in the (trans-) activation or (trans-) 
repression of target genes, there are non-genomic ef-
fects on the basis of the interference with membrane-as-
sociated receptors as well as with membrane lipids. In 
fact, various glucocorticoids appear to differ with respect 
to the relative infl uence on these targets. Thus, the ex-
tended knowledge of glucocorticoid-induced cellular 
signalling should allow the design and development of 
even more specifi cally acting drugs – as it has been ob-
tained with other steroids, e.g. estrogens for osteoporo-
sis prevention. 
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reported concerning topical glucocorticoid use in derma-
tology, recently this has also been acknowledged with re-
spect to asthma therapy  [6–10] . The understanding of this 
separation increases since several new aspects of the glu-
cocorticoid signalling pathways were revealed during the 
last years, expanding our knowledge on the mechanism 
of drug action. Various aspects of glucocorticoid action 
have been reviewed previously emphasising comparison 
of glucocorticoids and other immunomodulators  [11] , 
non-genomic glucocorticoid effects  [12–14] , cross-talk 
with cytokines and transcription factors  [15–18] , gluco-
corticoid-mediated apoptosis  [19] , receptor isoforms  [20] 
but also effects in asthma  [9, 21] . Here, we describe the 
multifaceted aspects of the mechanism of glucocorticoid 
action which are currently known and their translation 
into the therapy of infl ammatory skin diseases. 
 Infl uence on the Cytokine Network 
 An imbalance of helper T cells in atopic eczema and 
asthma results in an increased baseline mediator forma-
tion  [22] . Consequently, alveolar macrophages of asthma 
patients and keratinocytes of patients with atopic derma-
titis release interleukin-1 (IL-1), tumour necrosis factor-  
(TNF-  ) and granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) at an increased rate  [21, 23–25] . By 
stimulating cytokine receptors on the cell surface, IL-1 
and TNF-  induce a cellular signal cascade which acti-
vates transcription factors such as signal transducers and 
activators of transduction (STATs) or the nuclear factor 
  B (NF-  B) which is released from the complex with its 
inhibitory protein I  B  . Another relevant pathway of
IL-1 and TNF-  is the activation of the mitogen-activat-
ed protein (MAP) kinase, and thus the activation of acti-
vator protein 1 (AP-1) which also results in the activation 
of nuclear factor of activated T cells (NFAT) containing 
AP-1 as an integral part. AP-1 and NF-  B activate re-
sponse genes by binding to their promotor region, recruit-
ment of co-activators and basal transcription factors. His-
tone acetylation by activated histone acetyl transferases 
results in a more relaxed chromatin environment which 
enables the access of RNA polymerase to the coding re-
gion of the target gene. These are genes coding for cyto-
kines (IL-1, IL-2, IL-4, IL-6, IL-13, TNF-  ), chemotaxis 
proteins (e.g., GM-CSF), cellular adhesion molecules, i.e. 
intercellular adhesion molecule (ICAM-1), vascular cell 
adhesion molecule (VCAM-1), but also enzymes, i.e. 
phospholipase A 2 ,  inducible forms of cyclooxygenase 
(COX-2) and NO synthase (iNOS). 
 By inducing cellular adhesion molecules, proinfl am-
matory cytokines (e.g., TNF  , IL-1) increase epidermal 
chemokine formation and T cell localisation. CCL17 and 
CCL22, chemokines with two highly conserved adjacent 
cysteine residues formed by IL-4 and IL-13 stimulation, 
recruit T cells to skin and lung. Keratinocytes from pa-
tients with atopic dermatitis express also other Th attrac-
tant chemokines such as RANTES, MCP-1 and – most 
importantly – CCL27 more abundantly  [23, 24] . 
 Most importantly, there is an intense cross-talk of the 
various signalling pathways described, and maximum ac-
tivation of a cell means the activation of more than a 
single pathway. Moreover, enzymes from the MAP ki-
nase pathway may also interact with the NF-  B cascade 
 [15, 16] . 
 By inhibiting the formation of infl ammatory cyto-
kines, glucocorticoids interfere with the activation of a 
variety of immunologic cells. Glucocorticoids inhibit the 
activation of dendritic cells which normally stimulate 
Th2 cells and in the lung also B cells. Moreover, eosino-
phil and T cell apoptosis increases. Yet, glucocorticoids 
also infl uence other cells such as keratinocytes, fi broblasts 
and alveolar cells. Besides genomic effects, non-genomic 
targets appear to contribute to glucocorticoid effects. 
 Genomic Glucocorticoid Effects 
 Receptor Structure 
 In general, steroid hormones induce their effects by 
binding to intracellular receptors (glucocorticoid recep-
tor, GR or hGR  ; mineralocorticoid receptor, MR; pro-
gesterone receptor, PR; androgen receptor, AR; estrogen 
receptor, ER; fi g.  1 ) which are closely interrelated and 
form a superfamily together with the receptors for thyroid 
hormone, retinoids, vitamin D but also the peroxisome 
proliferator activated receptor. Today, various isoforms 
of these receptors are known. These proteins are charac-
terised by an N-terminal domain activating gene expres-
sion, a central DNA-binding moiety and a C-terminal 
ligand-binding domain. 
 The highly conserved central DNA-binding domain of 
about 70 residues contains two loops which are stabilised 
by four cysteine residues each complexing to zinc ions 
(zinc fi ngers). The N-terminal zinc fi nger discriminates 
between the different response elements and therefore is 
important for the selectivity of glucocorticoid effects. The 
DNA-binding domain is fl anked by an N-terminal trans-
activating moiety (  1) which after receptor binding en-
hances the transcription of target genes. The ligand-bind-
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ing domain is built up from 12   -helices, the segment   2 
of the liganded receptor, which is part of helix 12, favours 
dimerisation and enhances transactivation but also inter-
actions with co-activators  [26] . The closest homology is 
found within the group of the 3-oxo-steroid receptors 
which besides GR are the MR, PR and AR. The ligand-
binding domains contain a central arginine and a gluta-
mine complexing the 3-keto group, while it is glutaminic 
acid and arginine of ER which interact with the phenolic 
group of the estrogens  [26, 27] . 
 Recently, the precise structure of the ligand-binding 
domain of GR was revealed by the crystallisation of this 
domain  [28] and independently by molecular modeling 
starting from the well-known ligand-binding domain of 
PR  [29, 30] . The C-terminal 12 helices of the GR fold 
into a three-layer sandwich which embeds the hydropho-
 Fig. 1. Human glucocorticoid receptor gene, 
mRNA splice variants and receptor pro-
teins (hGR  and hGR  ); modifi ed from 
 [20] . 
 Fig. 2. Glucocorticoid receptor binding as 
determined experimentally  [30, 81] . BM = 
Betamethasone; BMP = betamethasone di-
propionate; BMV = betamethasone 17-val-
erate; BU = budesonide; CBP = clobetasol 
17-propionate; DEX = dexamethasone; 
MOM = mometasone; MPD = methylpred-
nisolone; PC = prednicarbate; PD = pred-
nisolone; TAA = triamcinolone acetonide. 
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bic pocket for the ligand. In contrast to other nuclear re-
ceptors, there is a rather wide side pocket which allows 
access of many steroid esters favoured for the topical 
treatment of infl ammatory skin diseases and bronchial 
asthma. Results of ligand docking experiments to predict 
glucocorticoid activity conformed to steroid binding de-
termined experimentally. As depicted in fi gure  2 , there is 
a close correlation of GR binding predicted by quantita-
tive structure activity calculations and the binding data 
determined experimentally. Extending the set of 17 ste-
roids  [30] by another seven (table  1 ) the only exception is 
fl uticasone propionate, calculation of binding data is ex-
cluded since this agent is the only carbothiolate drug. 
 Non-stimulated GRs form a complex with various re-
ceptor-associated proteins (RAPs) which mask the li-
gand-binding domain. RAPs are chaperones (heat shock 
proteins hsp90 and hsp70) which ensure correct folding 
of the receptor protein and co-chaperones such as the im-
munophilin FKB51  [18] , a FK506 (tacrolimus)-binding 
protein. 
 Receptor Activation, Response Elements, 
Transactivation and Transrepression 
 Glucocorticoid binding induces hyperphosphoryla-
tion, exchange of immunophilins (FKB52 replaces 
FKB51) and recruitment of the transport protein dynein 
which allows nuclear translocation of the receptor. In the 
nucleus, ligand-activated GRs release hsp90 and change 
structure  [18] which allows the formation of a unique ho-
modimer characterised by a   -sheet made up from the 
dimerisation domains of both monomers  [28] . GR di-
mers as transcription factors bind to specifi c DNA-bind-
ing elements (glucocorticoid response elements; GREs) 
and infl uence the expression of target genes which har-
bour the respective response elements in their promotor 
region (simple GRE, transactivation; fi g.  3 a). Simple 
GREs are imperfect palindromic 15-base-pair sequences 
which are recognised by the zinc fi ngers of the DNA-bind-
ing domains of activated receptors. Gene inducibility in-
creases with the numbers of response elements in the vi-
cinity of the polymerase-binding moiety. Composite 
GREs allow additional binding for non-receptor factors 
Table 1. Glucocorticoid receptor binding predicted from quantitative structure activity calculations and experi-
mentally determined [30, 81, 82], IC50 values for genomic and non-genomic effects in A549 cells [7] and relative 
activity in rheumatic diseases [13]









< 8.30 7.00 7.70 7.70 1.2
Methylprednisolone 7.39 7.43 < 8.30 NS 8.00 8.00 1.0
Fluticasone NR 9.3 <12.00 9.30 9.30 NS ND
Mometasone 8.97 8.79
9.12
<12.00 10.00 11.00 NS ND
Budesonide 8.481 9.00 <10.30 9.00 9.00 NS ND
Beclomethasone dipropionate 8.701 ND <12 9.12 9.12 NS ND
Beclomethasone 7.861 ND < 9.60 6.70 7.70 7.70 ND
Prednylidene 7.521 ND <ND ND ND ND 3.0
Prednisolone 7.12 6.99 < 9.00 7.30 7.30 NS 0.4
Betamethasone 8.07 7.60 <ND ND ND ND 0.2
Betamethasone 17-valerate 9.38 9.15 <ND ND ND ND ND
Betamethasone dipropionate 8.08 8.20 <ND ND ND ND ND
Prednicarbate 7.81 7.89 <ND ND ND ND ND
Clobetasol 17-propionate 9.65 9.82 <ND ND ND ND ND
Hydrocortisone 7.201 ND < 8.00 7.12 7.12 7.12 ND
Triamcinolone acetonide 8.441 8.31 < 7.60 6.70 6.70 6.70 ND
ND = Not determined; NR = reliable results not to be expected; NS = not signifi cant.
1 Recalculated as described by [30].
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 [18] . Glucocorticoid-induced transactivation is seen, e.g. 
with genes related to gluconeogenesis, arterial blood pres-
sure and intraocular tension which harbour GREs as does 
the gene encoding the    2 -adrenoceptor. 
 Besides inducing gene expression by binding of a ho-
modimer to a GRE, glucocorticoids may also inhibit gene 
expression either by the binding of liganded monomers 
to a promotor containing negative GREs (nGREs; fi g.  3 b) 
or by the sequestration or inhibition of basal transcription 
factors (fi g.  3 c–e). nGREs differ in structure from classic 
GREs and were fi rst described for the proopiomelanocor-
tic gene  [21] and then for others, e.g. the IL-1  gene  [18] . 
In epidermal cells, the synthesis of basal-cell-specifi c (K5, 
K14) and disease-associated keratins (K6, K16, K17) is 
under the control of four nGREs  [31] . Another form of 
inhibited gene expression has been known even longer. 
This is due to the complex formation of liganded GR 
monomers and the basal transcription factors described 
above which then become inactivated either by sequestra-
tion (fi g.  3 c), masking of transactivation domains (fi g.  3 d) 
or steric hindrance of the basal transcription machinery 
(fi g.  3 e). Residues of the GR DNA and ligand-binding 
domains interact with AP-1, the DNA-binding domain is 
involved in the complex formation with NF-  B. 
 Helix 12 of the activated GR allows co-activator and/
or co-repressor interaction  [28] , including the steroid re-
ceptor co-activator (SRC)-1 and the cAMP-responsive el-
ement-binding protein (CREB)-binding protein (CBP). 
Increasing histone acetylation co-activators (fi g.  3 f) weak-
en histone-chromatine interactions which enables poly-
merase to initiate transcription, while the opposite holds 
true with histone deacetylase. By binding to co-factors, 
glucocorticoids reverse these effects on gene expression. 
In addition, glucocorticoids may infl uence gene expres-
sion by histone methylation and phosphorylation (for re-
view, see  [9] ). 
 Fig. 3. Models describing glucocorticoid in-
teractions with DNA and transcription fac-
tors (modifi ed from  [18] ; for details see 
text). 
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 Another genomic effect includes the increase in gluco-
corticoid-inducible leucin zipper and thus AP-1  [18] and 
NF-  B formation in macrophages  [32] . Inhibition of lym-
phocyte and monocyte activation by the NF-  B pathway 
(fi g.  3 g) is due to an enhanced transcription of the I  B  
gene  [21, 33, 34] which, however, is not the case with mu-
rine fi broblasts, endothelial cell lines  [35] and human ke-
ratinocytes  [5] . Table  2 summarises signalling pathways 
which are infl uenced by glucocorticoids. 
 Moreover, glucocorticoids interfere with the forma-
tion of infl ammatory proteins also at the post-transcrip-
tional level by mRNA destabilisation as described for, 
e.g., TNF-  , IL-1, IL-2, IL-6, COX-2 and iNOS  [18] . 
 Glucocorticoid Antagonists 
 As with other nuclear receptors, GR antagonists have 
been developed. Most frequently used for in vitro and 
animal experiments is RU486 (mifepristone) which in-
hibits dexamethasone-induced transactivation, while it 
acts as a partial agonist with respect to AP-1 and NF-  B 
suppression  [36–38] . RU486 also induces immunophilin 
exchange, dynein recruitment and nuclear translocation 
 [39] . In man, RU486 suppresses the symptoms and signs 
of hypercortisolism and dexamethasone-induced pitu-
itary inhibition and skin blanching  [40] . Most interest-
ingly, the glucocorticoid antagonist ZK98299 acts in a 
more specifi c manner as the liganded GR does not inter-
fere with NF-  B activity  [36, 37] . This distinct interac-
tion offers the horizon to more selective GR ligands. 
 Receptor Isoforms 
 Several isoforms of the human GR can be differenti-
ated. Only in rare cases, however, point mutations or 
splice variants may result in diseases, e.g. rare forms of 
the glucocorticoid resistance syndrome  [20] . The most 
important form is the broadly distributed   -form (hGR  ; 
fi g.  1 ) containing 777 amino acids which is expressed in 
high amounts in almost all cell types including keratino-
cytes and fi broblasts  [41] , endothelial cells of blood ves-
sels and the airway epithelium as well as the epithelium 
of bronchial vessels  [21] . 
 Breslin et al.  [42] identifi ed two more exons upstream 
of exon 1, which can translate into exon 1 of the hGR 
protein; these are therefore named exons 1A and 1B, 
while exon 1, known for a longer period now, is called 
exon 1C. Moreover, alternative translation initiation of 
exon 1 (1C) results in the formation of a B isoform of 
hGR  which consists of 751 residues  [43] . Currently, the 
tissue distribution and possible differences in function of 
the isoforms differing in the transactivating domain await 
to be discovered. 
 Another broadly distributed isoform, named hGR  , is 
generated from a splice variant of exon 9 of the GR gene 
and is found in human tissues (e.g., lung, thymus, lympho-
cytes, brain, heart, muscle), though it is present at a lower 
rate as compared with hGR  (1:  40–2,800)  [20] . Both iso-
forms are identical until amino acid 727, then 15 different 
residues follow in hGR  . Due to the truncated C-terminal 
domain, hGR  does not bind ligands any more and is 
transcriptionally inactive itself. Early investigations sug-
gested a negative effect of hGR  on hGR  effects  [44, 45] . 
This, however, may be related to some tissues or cell states 
only  [20] . A protective effect of hGR  against dexameth-
asone induced apoptosis of human neutrophils  [46] and a 
correlation of hGR  expression, and glucocorticoid resis-
tance were described  [47–49] . Yet, the relevance of hGR  
for asthma is still under debate  [9, 49, 50] . Following co-
transfection of hGR  and hGR  genes, transactivation 
declined by 40% in COS-7 cells and to a lesser extent in 
the lung carcinoma cell line A549. Most interestingly, 
overexpression of either isoform inhibited transrepression 
– even in the absence of dexamethasone stimulation which 
might be due to complex formation of even the non-ligan-
ded GR and transcription factors  [50] . 
Inhibition of Gene Transcription factor
Cytokines IL-2 NF-AT, AP-1, NF-B
IL-6 NF-B, AP-1
TNF- , GM-CSF, IL-1 NF-B
IFN- AP-1
Enzymes iNOS, COX-2 NF-B
collagenase AP-1
Adhesion molecules ICAM-1, E-selectin, VCAM-1 NF-B
Skin proliferation keratin GR monomer (nGRE)
collagenase AP-1
Table 2. Glucocorticoid activation and 
suppression of genes relevant for the 
 effi cacy in infl ammatory skin diseases and 
skin atrophy induction (from [18])
 New Aspects of Glucocorticoid Action  Skin Pharmacol Physiol 2005;18:103–114 109
 hGR  mRNA also clearly dominates in primary cul-
tures of human keratinocytes (328-fold) and fi broblasts 
(710-fold) over hGR  mRNA. Increasing hGR  over 
hGR  fi vefold by cotransfection of COS-7 cells did not 
reduce the binding of glucocorticoids and RU486 signifi -
cantly  [41] . In skin biopsies, hGR  is upregulated during 
tuberculin response  [48] . All these ratios, however, have 
to be interpreted with caution since mRNA ratios must 
not translate 1:  1 to the protein level and the quantifi ca-
tion of the protein is related to antibody specifi city. 
 Another truncated splice variant (GR-  ; exon 8) de-
tected in tumour cells or the rather ubiquitously expressed 
hGR-  do not seem to be of major clinical relevance  [20] . 
Yet, this may be different with two other recently de-
scribed polymorphisms. An S651F mutation of hGR  
was identifi ed in immortalised lymphocytes isolated from 
atopic Japanese, resulting in the formation of a less stable 
and therefore less active GR protein. Stability of mRNA 
was even more reduced if adenine was inserted into posi-
tion 2314 of hGR  gene. Detected with lymphocytes tak-
en from patients suffering from lupus nephritis, this poly-
morphism may reduce the effi cacy of glucocorticoid ther-
apy  [51] . 
 Concerning tissue specifi city, another GR polymor-
phism deserves to be mentioned, which is due to alterna-
tive splicing of human GR gene by two forms of the DNA 
restriction enzyme BclI. While this does not change the 
coding region of the GR gene, it may infl uence the regu-
lating region  [18] . Most interestingly, the large variant of 
the restriction enzyme was linked to increased sensitivity 
to budesonide-induced skin blanching, while dexametha-
sone more effi ciently inhibited lysozyme release from leu-
kocytes from subjects with the small allele  [52] . Once 
more, this hints at tissue-specifi c effects of various gluco-
corticoids. 
 In the context of GR isoforms, also the GR dim  mouse 
has to be mentioned, which is transfected with a GR iso-
form unable for dimer formation and thus transactiva-
tion, yet inducing transrepression as the wild type does. 
Therefore, in contrast to the GR knockout mice, the 
GR dim  mouse grows until adulthood  [53] . 
 Modulation of Responsiveness 
 Besides GR isoforms and the numbers and locations 
of GREs in the promotor, post-translational processes 
regulate glucocorticoid responsiveness. Hyperphosphor-
ylation of serins in the   1 region of the liganded GR en-
hances the response to steroids by favouring ligand bind-
ing, RAP binding and nuclear traffi cking, while GR
dephosphorylation reduces transactivation. Moreover, 
glucocorticoid response is infl uenced by the cross-talk of 
nuclear receptor signalling pathways, since the liganded 
GR does not only form a homodimer, but also heterodi-
mers with the other nuclear receptors and can compete 
with those for co-factors  [18] . Also receptor-associated 
immunophilins may induce a cross-talk with other signal-
ling cascades as to be derived from studies in synovial fi -
broblasts  [54] and the lung adenocarcinoma-derived A549 
cell  [8] stimulated with dexamethasone and FK506.  
 Recently, tyrosine nitration has been described as a 
mechanism to enhance GR hsp90 dissociation and anti-
infl ammatory activity. Nitration, including the impor-
tant Tyr735  [29] , was induced by a GR ligand carrying a 
nitration domain  [55] . This observation may stimulate 
the search for new and possibly more specifi c drugs. 
 Glucocorticoid Resistance 
 Whether hGR  is of relevance with respect to gluco-
corticoid resistance which occurs, e.g. in up to 10% of 
asthmatic subjects but also in other chronic infl amma-
tory diseases, currently remains open. Alternatively, a re-
duced number of activated GR within the nucleus, a lack 
of interaction with the basal transcription process, or a 
hyperactive MAP kinase pathway may be the reason for 
this steroid resistance  [15] . It can only be speculated 
whether one of these mechanisms may be of relevance 
also in glucocorticoid tachyphylaxia, which was a subject 
of major concern in the early days of topical glucocorti-
coid treatment of skin disease  [56] . 
 Non-Genomic Glucocorticoid Effects 
 While it takes at least 30 min for the genomic effects 
to become obvious in a cell culture experiment, it takes 
only seconds or a few minutes to detect non-genomic ef-
fects. As with other steroids, non-genomic targets were 
identifi ed also with glucocorticoids  [12–14] . Membrane-
associated receptors appear to be a specifi c isoform or a 
modifi cation of the classical GR. Steroid effects on mem-
brane-associated receptors encompass the activation of 
MAP kinase, adenylate cyclase and protein kinase C  [18] . 
Glucocorticoids inhibit the recruitment of signalling fac-
tors of activated epithelial growth factor receptors and 
thus phospholipase A 2  and arachidonic acid release  [57] . 
Investigations of various glucocorticoids in A549 cells al-
lowed to separate three types of glucocorticoids (table  1 ; 
fi g.  3 ). The conventional steroids dexamethasone, hydro-
cortisone, triamcinolone acetonide and beclomethasone 
induced both genomic (COX-2 expression, prostaglandin 
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E release and inhibition of cell growth) and non-genomic 
effects (phospholipase A 2  activation and arachidonic acid 
release). The latter was proven by its sensitivity to the 
SRC-1 inhibitor PP2 and insensitivity to the transloca-
tion inhibitor geldanamycin. In contrast, methylprednis-
olone exhibited only the non-genomic effect, while the 
newly developed steroids fl uticasone 17-propionate, mo-
metasone and budesonide but also beclomethasone di-
propionate did not induce phospholipase A 2  activity, yet 
selectively inhibited COX-2 expression, prostaglandin E 
release, and cell growth  [7] . In fact, these steroids are re-
ported to induce less side effects in asthma therapy as 
compared with conventional steroids. These data clearly 
indicate that a separation of glucocorticoid effects is pos-
sible. Since RU486 inhibited genomic and non-genomic 
effects, the latter should be induced by the stimulation of 
membrane-associated GR. 
 If applied at very high concentrations (prednisolone 
 1 200 mg), which are used for, e.g., shock therapy, gluco-
corticoids can also induce non-specifi c non-genomic ef-
fects, possibly due to a physical dissolution of the steroid 
molecule within the cell membrane. This results in a par-
tial uncoupling of oxidative phosphorylation, mitochon-
drial proton leak and a decrease of cellular entry of cal-
cium ions which may explain that high glucocorticoid 
doses are generally needed for acute exacerbations of im-
munological diseases. Relative glucocorticoid potencies 
for non-specifi c non-genomic effects  [58] clearly differ 
from potency for genomic effects (table  1 ). With respect 
to the topical treatment of skin disease or bronchial asth-
ma, local drug concentrations high enough to induce non-
specifi c non-genomic drug actions currently cannot be 
excluded. 
 Glucocorticoid Effects on the Skin 
 Despite of the recent introduction of calcineurin in-
hibitors into the topical treatment of eczema, glucocorti-
coids still are fi rst-line drugs, especially with respect to 
the acute treatment of the more severe forms  [1] . Yet, 
topical glucocorticoids are also indicated for other infl am-
matory skin diseases, as for example psoriasis. This is due 
to the inhibition of the formation of infl ammatory pro-
teins released from keratinocytes, fi broblasts and leuko-
cytes infi ltrating the skin. Unwanted effects most feared 
are skin thinning which is due to the inhibition of keratin 
synthesis of epidermal cells  [31] and, more importantly, 
to an impaired proliferation of fi broblasts  [5, 59, 60] and 
disturbed collagen metabolism in the dermis. In the rat, 
dexamethasone induced a drastical reduction of the fi bril 
type III collagen and – less – type I collagen. Moreover, 
this drug decreased collagenases which belong to the ma-
trix metalloproteinases (MMP) and tissue inhibitors of 
the metalloproteinases TIMP-1 and TIMP-2  [61] . In fact, 
collagenase (MMP-13) produced by basal keratinocytes 
is under AP-1 control and the formation is downregu-
lated by dexamethasone treatment of both wild-type and 
the GR dim  mice  [33] . Since type I and type III collagens 
primarily determine the tensile strength of the skin  [62] , 
this deterioration explains well striae formation which 
occurs in hypercortisolism and may follow long-term top-
ical treatment with glucocorticoids  [63] . Moreover, the 
effect on K5 and K14 explains epidermal thinning during 
long-term glucocorticoid treatment, inhibition of K6 and 
K16 the interference with wound healing. The additional 
effect on keratin synthesis via AP-1 inhibition may in-
crease glucocorticoid effects, since besides nGREs these 
keratin gene promotors also contain an AP-1 response site 
 [31] . 
 Glucocorticoids induce cytostatic and cytotoxic ef-
fects in a cell-specifi c manner  [62] . While apoptosis in-
duction is a well-known effect of glucocorticoids interfer-
ing with NF-  B in lymphocytes, and the inhibition of 
immune cells should contribute to its immunosuppres-
sive and anti-infl ammatory effects in eczema and psoria-
sis, skin thinning following glucocorticoids is not due to 
an increased apoptotic rate. In fact, despite an inhibition 
of NF-  B activity, dexamethasone protected fi broblasts 
against the TNF  , UV irradiation or ceramide-induced 
apoptosis by stimulating sphingosine 1-phosphate (S1P) 
formation. While NF-  B inhibitors did not abolish the 
antiapoptotic effect, the sphingosine kinase inhibitor 
N,N-dimethylsphingosine did so. This effect is cell spe-
cifi c as it was not seen with keratinocytes  [64] . Although 
we previously demonstrated that vitamin D 3  and the 
transforming growth factor-  stimulate fi broblast prolif-
eration via an increased sphingosine phosphorylation 
 [65, 66] and S1P then activates Smad proteins  [67] , the 
S1P-induced proliferation is obviously overrun by the an-
tiproliferative effect of glucocorticoids due to the inhibi-
tion of IL-1  and IL-6 release  [5] .  
 Glucocorticoids: Benefi t/Risk Ratio in Eczema 
Therapy 
 Since target diseases for glucocorticoid treatment are 
of chronic or relapsing nature, drugs effi cacious and safe 
in the long-run are of highest relevance. The unraveling 
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of signalling processes offers new perspectives for safer 
therapeutic strategies. Antiproliferative effects of topical 
glucocorticoids, however, do not parallel steroid potency 
in man  [68, 69] or cell culture  [5] . When looking into the 
molecular reason for the partial separation of wanted and 
unwanted effects obtained so far, one has to take the 
multi-faceted mechanism of action into account. 
 Comparing hGR  binding of 17 topical glucocorti-
coids widely varying in potency (prednisolone to clobeta-
sole 17-propionate) did not allow to detect an infl uence 
of receptor affi nity on the benefi t/risk ratio. In fact, bind-
ing of less atrophogenic steroids fi tted well into the spec-
trum of the more toxic agents  [30] . Moreover, calculated 
receptor binding of six glucocorticoids studied for their 
infl uence on A549 cells are well in accordance with previ-
ous data (table  1 , fi g.  2 ). Yet as with asthma, the differ-
ences in the benefi t/risk ratio in eczema may result from 
differences in transrepression, transactivation and spe-
cifi c non-genomic effects  [7] undistinguished by receptor 
binding. Interestingly, low glucocorticoid concentrations 
appear to induce transrepression more potently than 
transactivation  [9] . The infl uence on NF-  B transrepres-
sion, however, did not refl ect the potential in skin dis-
eases. Indeed, clobetasol propionate activity only slightly 
exceeded the hydrocortisone effect  [38] . Differentiating 
steroids with a favourable effect on transrepression in vi-
tro  [70, 71] , however, failed in the animal experiment 
 [72] . Therefore, additional targets appear of relevance. 
 Mometasone and the relatively equipotent fl uticasone 
propionate  [73] both belong to the group of glucocorti-
coids with an improved benefi t/risk ratio  [69] . At lower 
concentrations, they bind preferentially to GR mono-
mers, and induce dimer formation only at higher concen-
trations  [6] . In addition, a separation of budesonide and 
dexamethasone effects has been described in subjects ex-
pressing different GR isoforms  [52] . 
 Therefore, the specifi c interaction of a glucocorticoid 
with the GR may infl uence the structure of the receptor 
surface and thus its interaction with other proteins and 
GREs. In fact, recently differing requirements of GR tar-
gets for   1 and   2 structures were reported  [62] , and full 
and partial GR agonists differing in D ring structure in-
duce different receptor conformational changes  [29] . In-
terestingly, prednicarbate, which proved less atrophogen-
ic than betamethasone 17-valerate and also less than mo-
metasone  [69] , turned out as a partial agonist with the 
N564A mutant of hGR   [30] . 
 Since glucocorticoid effects depend on the cell type, 
cell culture experiments, especially if performed in cell 
lines or using protein overexpression, may not exactly 
refl ect glucocorticoid effects in vivo. In fact, glucocorti-
coids less atrophogenic to the skin (mometasone furoate, 
fl uticasone propionate) strongly inhibit the proliferation 
of A549 cells (table  1 )  [7] . Detecting skin-specifi c effects 
asks for studies in vivo or at least in primary skin cell 
cultures. Doing so, however, does not eliminate the ‘time’ 
factor, since cell culture experiments are run for some 
hours, while the treatment of skin diseases lasts for days 
or even weeks which allows for adaptative processes. 
Therefore, it is to be expected that in vivo experiments 
will improve further our understanding of glucocorticoid-
related differences in wanted and unwanted effects. 
 Future Developments 
 Glucocorticoid research is an ongoing process for more 
than 50 years, and its intensity is currently increasing. 
New congeners of a somewhat improved benefi t/risk ratio 
have been developed  [63] , more selective ones are to be 
expected. Current research aims at designing drugs induc-
ing selective transrepression  [71, 72] or enhancing bind-
ing by nitrotyrosine formation  [55] . Increasing target se-
lectivity at the molecular level, however, may bear the 
risk of a major loss in effi cacy. 
 An alternative for a safer eczema therapy therefore 
encompasses drug carrier systems for epidermal glucocor-
ticoid targeting  [74, 75] . Moreover, combined treatment 
with tretinoin should reduce skin atrophy  [76, 77] , and 
ointment preparations containing a glucocorticoid plus a 
vitamin D analogue may improve psoriasis therapy by 
reducing side effects  [78] . Studies in rheumatoid syno-
vial  [54] and murine skin fi broblasts  [79] also indicate a 
synergistic effect of tacrolimus and low-dose dexametha-
sone which may translate into clinical improvement. Due 
to the still measurable potential for skin atrophy of glu-
cocorticoids and the lower potency and the risk of photo-
carcinogenesis with tacrolimus and pimecrolimus  [80] , a 
combination therapy that is safe and effective in long-
term treatment of severe cases would be welcome. 
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